Are transgenic mice the 'alkahest' to understanding myocardial hypertrophy and failure?

Journal of Molecular and Cellular Cardiology

Volumn 46, Issue 2, 2009, Pages 118-129

  Cook, Stuart A ^a   Clerk, Angela ^a   Sugden, Peter H ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

myosin heavy chain promoter; Cardioselectivity; End points; Extracellular signal regulated kinase 1 2 cascade; Genetic background and strain effects; Glycogen synthase kinase 3; Intracellular localisation; Poison proteins; Protein kinase B Akt; Ryanodine receptor 2; Signal strength matching; Trangenesis

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RYANODINE RECEPTOR 2;

CELLULAR DISTRIBUTION; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; HEART; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSGENE; TRANSGENIC MOUSE; TRANSGENICS;

ANIMALS; CARDIOMEGALY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCOGEN SYNTHASE KINASE 3; HEART FAILURE; MICE; MICE, TRANSGENIC; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

MURINAE; MUS MUSCULUS;

EID: 58149288067     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2008.11.005     Document Type: Review

References (104)

1. Field L.J. Atrial natriuretic factor-SV40 T antigen transgenes produce tumors and cardiac arrhythmias in mice. Science 239 (1988) 1029-1033
2. Clerk A., Cullingford T.E., Fuller S.J., Giraldo A., Markou T., Pikkarainen S., et al. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J. Cell Physiol. 212 (2007) 311-322
3. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93 (1998) 215-228
4. Wilkins B.J., and Molkentin J.D. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem. Biophys. Res. Commun. 322 (2004) 1178-1191
5. Barinaga M. Signaling path may lead to better heart-failure therapies. Science 280 (1998) 383
6. Kennedy R.A., Kemp T.J., Sugden P.H., and Clerk A. Using U0126 to dissect the role of the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade in the regulation of gene expression by endothelin-1 in cardiac myocytes. J. Mol. Cell. Cardiol. 41 (2006) 236-247
7. Cullingford T.E., Markou T., Fuller S.J., Giraldo A., Pikkarainen S., Zoumpoulidou G., et al. Temporal regulation of expression of immediate early and second phase transcripts by endothelin-1 in cardiomyocytes. Genome Biol. 9 (2008) R32
8. Zhou Q., Renard J.P., Le Friec G., Brochard V., Beaujean N., Cherifi Y., et al. Generation of fertile cloned rats by regulating oocyte activation. Science 302 (2003) 1179
9. James J., Sanbe A., Yager K., Martin L., Klevitsky R., and Robbins J. Genetic manipulation of the rabbit heart by transgenesis. Circulation 101 (2000) 1715-1721
10. Subramaniam A., Jones W.K., Gulick J., Wert S., Neumann J., and Robbins J. Tissue-specific regulation of the α-myosin heavy chain gene promoter in transgenic mice. J. Biol. Chem. 266 (1991) 24613-24620
11. Palermo J., Gulick J., Ng W., Grupp I.L., Grupp G., and Robbins J. Remodeling the mammalian heart using transgenesis. Cell. Mol. Biol. Res. 41 (1995) 501-509
12. O'Brien T.X., Lee K.J., and Chien K.R. Positional specification of ventricular myosin light chain 2 expression in the primitive murine heart tube. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 5157-5161
13. Johnson J.E., Wold B.J., and Hauschka S.D. Muscle creatine kinase sequence elements regulating skeletal and cardiac muscle expression in transgenic mice. Mol. Cell. Biol. 9 (1989) 3393-3399
14. Brüning J.C., Michael M.D., Winnay J.N., Hayashi T., Hörsch D., Accili D., et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell 2 (1998) 559-569
15. Lee K.J., Ross R.S., Rockman H.A., Harris A.N., O'Brien T.X., van Bilsen M., et al. Myosin light chain-2 luciferase transgenic mice reveal distinct regulatory programs for cardiac and skeletal muscle-specific expression of a single contractile protein gene. J. Biol. Chem. 267 (1992) 15875-15885
16. Trask R.V., and Billadello J.J. Tissue-specific distribution and developmental regulation of M and B creatine kinase mRNAs. Biochim. Biophys. Acta 1049 (1990) 182-188
17. Lyons G.E., Schiaffino S., Sassoon D., Barton P., and Buckingham M. Developmental regulation of myosin gene expression in mouse cardiac muscle. J. Cell Biol. 111 (1990) 2427-2436
18. Ng W.A., Grupp I.L., Subramaniam A., and Robbins J. Cardiac myosin heavy chain mRNA expression and myocardial function in the mouse heart. Circ. Res. 68 (1991) 1742-1750
19. Izumo S., Lompré A.M., Matsuoka R., Koren G., Schwartz K., Nadal-Ginard B., et al. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J. Clin. Invest. 79 (1987) 970-977
20. Schuyler G.T., and Yarbrough L.R. Changes in myosin and creatine kinase mRNA levels with cardiac hypertrophy and hypothyroidism. Basic Res. Cardiol. 85 (1990) 481-494
21. D'Angelo D.D., Sakata Y., Lorenz J.N., Boivin G.P., Walsh R.A., Liggett S.B., et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 8121-8126
22. Cook S.A., Matsui T., Li L., and Rosenzweig A. Transcriptional effects of chronic Akt activation in the heart. J. Biol. Chem. 277 (2002) 22528-22533
23. Davisson R.L., Nuutinen N., Coleman S.T., and Sigmund C.D. Inappropriate splicing of a chimeric gene containing a large internal exon results in exon skipping in transgenic mice. Nucleic Acids Res. 24 (1996) 4023-4028
24. Giraldo P., and Montoliu L. Size matters: use of YACs, BACs and PACs in transgenic animals. Transgenic Res. 10 (2001) 83-103
25. Hirota H., Chen J., Betz U.A.K., Rajewsky K., Gu Y., Ross Jr. J., et al. Loss of a gp130 cardiac muscle cell survival pathway is critical in the onset of heart failure during biomechanical stress. Cell 97 (1999) 189-198
26. Geisterfer-Lowrance A.A.T., Christe M., Conner D.A., Ingwall J.S., Schoen F.J., Seidman C.E., et al. A mouse model of familial hypertrophic cardiomyopathy. Science 272 (1996) 731-734
27. McMahon M. Steroid receptor fusion proteins for conditional activation of Raf-MEK-ERK signaling pathway. Methods Enzymol. 332 (2001) 401-417
28. Tarutani M., Cai T., Dajee M., and Khavari P.A. Inducible activation of Ras and Raf in adult epidermis. Cancer Res. 63 (2003) 319-323
29. Xiao G., Mao S., Baumgarten G., Serrano J., Jordan M.C., Roos K.P., et al. Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis. Circ. Res. 89 (2001) 1122-1129
30. Gossen M., and Bujard H. Studying gene function in eukaryotes by conditional gene inactivation. Annu. Rev. Genet. 36 (2002) 153-173
31. Crone S.A., Zhao Y.-Y., Fan L., Gu Y., Minamisawa S., Liu Y., et al. ErbB2 is essential for prevention of dilated cardiomyopathy. Nat. Med. 8 (2002) 459-465
32. Özcelik C., Erdmann B., Pilz B., Wettschureck N., Britsch S., Hübner N., et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8880-8885
33. Parlakian A., Charvet C., Escoubet B., Mericskay M., Molkentin J.D., Gary-Bobo G., et al. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation 112 (2005) 2930-2939
34. Petrich B.G., Molkentin J.D., and Wang Y. Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination. FASEB J. 17 (2003) 749-751
35. Bueno O.F., De Windt L.J., Tymitz K.M., Witt S.A., Kimball T.R., Klevitsky R., et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19 (2000) 6341-6350
36. Cohen P., and Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2 (2001) 769-776
37. Frame S., and Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359 (2001) 1-16
38. Markou T., Cullingford T.E., Giraldo A., Weiss S.C., Alsafi A., Fuller S.J., et al. Glycogen synthase kinases 3α and 3β in cardiac myocytes: regulation and consequences of their inhibition. Cell Signal. 20 (2008) 206-218
39. Stambolic V., and Woodgett J.R. Mitogen inactivation of glycogen synthase kinase-3β in intact cells by serine 9 phosphorylation. Biochem. J. 303 (1994) 701-704
40. Kerkelä R., Woulfe K., and Force T. Glycogen synthase kinase-3β - actively inhibiting hypertrophy. Trends Cardiovasc. Med. 17 (2007) 91-96
41. Antos C.L., McKinsey T.A., Frey N., Kutschke W., McAnally J., Shelton J.M., et al. Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 907-912
42. Sanbe A., Gulick J., Hanks M.C., Liang Q., Osinska H., and Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ. Res. 92 (2003) 609-616
43. Michael A., Haq S., Chen X., Hsich E., Cui L., Walters B., et al. Glycogen synthase kinase-3β regulates growth, calcium homeostasis, and diastolic function in the heart. J. Biol. Chem. 279 (2004) 21383-21393
44. Luckey S.W., Mansoori J., Fair K., Antos C.L., Olson E.N., and Leinwand L.A. Blocking cardiac growth in hypertrophic cardiomyopathy induces cardiac dysfunction and decreased survival only in males. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H838-H845
45. Zhai P., Gao S., Holle E., Yu X., Yatani A., Wagner T., et al. Glycogen synthase kinase-3α reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases. J. Biol. Chem. 282 (2007) 33181-33191
46. Hirotani S., Zhai P., Tomita H., Galeotti J., Marquez J.P., Gao S., et al. Inhibition of glycogen synthase 3β during heart failure is protective. Circ. Res. 101 (2007) 1164-1174
47. McManus E.J., Sakamoto K., Armit L.J., Ronaldson L., Shpiro N., Marquez R., et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J. 24 (2005) 1571-1583
48. Bogoyevitch M.A., Glennon P.E., Andersson M.B., Clerk A., Lazou A., Marshall C.J., et al. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. J. Biol. Chem. 269 (1994) 1110-1119
49. raf-1. EMBO J. 13 (1994) 1610-1619
50. Lips D.J., Bueno O.F., Wilkins B.J., Purcell N.H., Kaiser R.A., Lorenz J.N., et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 109 (2004) 1938-1941
51. Harris I.S., Zhang S., Treskov I., Kovacs A., Weinheimer C., and Muslin A.J. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110 (2004) 718-723
52. Owens D.M., and Keyse S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26 (2007) 3203-3213
53. Bueno O.F., De Windt L.J., Lim H.W., Tymitz K.M., Witt S.A., Kimball T.R., et al. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vivo and in vitro. Circ. Res. 88 (2001) 88-96
54. Purcell N.H., Wilkins B.J., York A., Saba-El-Leil M.K., Meloche S., Robbins J., et al. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 14074-14079
55. Nakamura T., Colbert M., Krenz M., Molkentin J.D., Hahn H.S., Dorn II G.W., et al. Mediating ERK1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J. Clin. Invest. 117 (2007) 2123-2132
56. Bers D.M. Cardiac ryanodine receptor phosphorylation: target sites and functional consequences. Biochem. J. 396 (2006) e1-e3
57. Zalk R., Lehnart S.E., and Marks A.R. Modulation of the ryanodine receptor and intracellular calcium. Annu. Rev. Biochem. 76 (2007) 367-385
58. Bridge J.H.B., and Savio-Galimberti E. What are the consequences of phosphorylation and hyperphosphorylation of ryanodine receptors in normal and failing heart?. Circ. Res. 102 (2008) 995-997
59. Sharma M.R., Jeyakumar L.H., Fleischer S., and Wagenknecht T. Three-dimensional visualization of FKBP12.6 binding to an open conformation of cardiac ryanodine receptor. Biophys. J. 90 (2006) 164-172
60. Xin H.-B., Senbonmatsu T., Cheng D.-S., Wang Y.-X., Copello J.A., Ji G.-J., et al. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature 416 (2002) 334-338
61. Wehrens X.H.T., Lehnart S.E., Huang F., Vest J.A., Reiken S.R., Mohler P.J., et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 113 (2003) 829-840
62. Antos C.L., Frey N., Marx S.O., Reiken S., Gaburjakova M., Richardson J.A., et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ. Res. 89 (2001) 997-1004
63. Wehrens X.H.T., Lehnart S.E., Reiken S., Vest J.A., Wronska A., and Marks A.R. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 511-518
64. MacDonnell S.M., García-Rivas G., Scherman J.A., Kubo H., Chen X., Valdivia H., et al. Adrenergic regulation of cardiac contractility does not involve phosphorylation of the cardiac ryanodine receptor at Serine 2808. Circ. Res. 102 (2008) e65-e72
65. Benkusky N.A., Weber C.S., Scherman J.A., Farrell E.F., Hacker T.A., John M.C., et al. Intact β-adrenergic response and unmodified progression toward heart failure in mice with genetic ablation of a major protein kinase A phosphorylation site in the cardiac ryanodine receptor. Circ. Res. 101 (2007) 819-829
66. Lehnart S., and Marks A.R. Regulation of ryanodine receptors in heart. Circ. Res. 101 (2007) 746-749
67. Manolio T.A., Brooks L.D., and Collins F.S. A HapMap harvest of insights into the genetics of common disease. J. Clin. Invest. 118 (2008) 1590-1605
68. Shiraishi I., Melendez J., Ahn Y., Skavdahl M., Murphy E., Welch S., et al. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ. Res. 94 (2004) 884-891
69. Chiloeches A., Paterson H.F., Marais R., Clerk A., Marshall C.J., and Sugden P.H. Regulation of Ras.GTP loading and Ras-Raf association in neonatal rat ventricular myocytes by G protein-coupled receptor agonists and phorbol ester. Activation of the ERK cascade by phorbol ester is mediated by Ras. J. Biol. Chem. 274 (1999) 19762-19770
70. Satoh T., Endo M., Nakamura S., and Kaziro Y. Analysis of guanine nucleotide bound to ras protein in PC12 cells. FEBS Lett. 236 (1988) 185-189
71. Hunter J.J., Tanaka N., Rockman H.A., Ross Jr. J., and Chien K.R. Ventricular expression of a MLC-2-v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J. Biol. Chem. 270 (1995) 23173-23178
72. Vanhaesebroeck B., and Alessi D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 346 (2000) 561-576
73. Bhaskar P.T., and Hay N. The two TORCs and Akt. Dev. Cell 12 (2007) 487-502
74. Matsui T., Li L., Wu J.C., Cook S.A., Nagoshi T., Picard M.H., et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J. Biol. Chem. 277 (2002) 22896-22901
75. Rota M., Boni A., Urbanek K., Padin-Iruegas M.E., Kajstura T.J., Fiore G., et al. Nuclear targeting of Akt enhances ventricular function and myocyte contractility. Circ. Res. 97 (2005) 1332-1341
76. Tsujita Y., Muraski J., Shiraishi I., Kato T., Kajstura J., Anversa P., et al. Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 11946-11951
77. Harada H., Andersen J.S., Mann M., Terada N., and Korsmeyer S.J. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9666-9670
78. Cheng X., Ma Y., Moore M., Hemmings B.A., and Taylor S.S. Phosphorylation and activation of cAMP-dependent protein kinase by phosphoinositide-dependent protein kinase. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9849-9854
79. Moore M.J., Kanter J.R., Jones K.C., and Taylor S.S. Phosphorylation of the catalytic subunit of protein kinase A. Autophosphorylation versus phosphorylation by phosphoinositide-dependent kinase-1. J. Biol. Chem. 277 (2002) 47878-47884
80. Dorn II G.W., Robbins J., and Sugden P.H. Phenotyping hypertrophy: eschew obfuscation. Circ. Res. 92 (2003) 1171-1175
81. Dorn II G.W. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 49 (2007) 962-970
82. Hill J.A., and Olson E.N. Cardiac plasticity. N. Engl. J. Med. 358 (2008) 1370-1380
83. Huang W.-Y., Aramburu J., Douglas P.S., and Izumo S. Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy. Nat. Med. 6 (2000) 482-483
84. Buerger A., Rozhitskaya O., Sherwood M.C., Dorfman A.L., Bisping E., Abel E.D., et al. Dilated cardiomyopathy resulting from high level myocardial expression of Cre recombinase. J. Card. Fail. 12 (2006) 392-398
85. Drake T.A., Schadt E.E., and Lusis A.J. Integrating genetic and gene expression data: application to cardiovascular and metabolic traits in mice. Mamm. Genome 17 (2006) 466-479
86. Petretto E., Mangion J., Dickens N.J., Cook S.A., Kumaran M.K., Lu H., et al. Heritability and tissue specificity of expression quantitative trait loci. PloS Genet. 2 (2006) e172
87. Cerutti C., Kurdi M., Bricca G., Hodroj W., Paultre C., Randon J., et al. Transcriptional alterations in the left ventricle of three hypertensive rat models. Physiol. Genomics 27 (2006) 295-308
88. Petretto E., Sarwar R., Grieve I., Lu H., Kumaran M.K., Muckett P.J., et al. Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat. Genet. 40 (2008) 546-552
89. Taft R.A., Davisson M., and Wiles M.V. Know thy mouse. Trends Genet. 22 (2006) 649-653
90. Barrick C.J., Rojas M., Schoonhoven R., Smyth S.S., and Threadgill D.W. Cardiac response to pressure overload in 129S1/SvlmJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. Am. J. Physiol., Heart Circ. Physiol. 292 (2007) H2119-H2130
91. Maron B.J., and Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation 114 (2006) 1633-1644
92. Hilfiker-Kleiner D., Kaminski K., Podewski E., Bonda T., Schaefer A., Sliwa K., et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128 (2007) 589-600
93. Hilfiker-Kleiner D., Sliwa K., and Drexler H. Peripartum cardiomyopathy: recent insights in its pathophysiology. Trends Cardiovasc. Med. 18 (2008) 173-179
94. Hilfiker-Kleiner D., Meyer G.P., Schieffer E., Goldmann B., Podewski E., Struman I., et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J. Am. Coll. Cardiol. 50 (2007) 2354-2355
95. Fett J.D. Caution in the use of bromocriptine in peripartum cardiomyopathy. J. Am. Coll. Cardiol. 51 (2008) 2083
96. Baines C.P., Kaiser R.A., Purcell N.H., Blair N.S., Osinska H., Hambleton M.A., et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434 (2005) 658-662
97. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434 (2005) 652-658
98. Nishino Y., Webb I.G., Davidson S.M., Ahmed A.I., Clark J.E., Jacquet S., et al. Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in mouse. Circ. Res. 103 (2008) 307-314
99. Tong H., Imahashi K., Steenbergen C., and Murphy E. Phosphorylation of glycogen synthase kinase-3β during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ. Res. 90 (2002) 377-379
100. 2+ release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum. J. Biol. Chem. 265 (1990) 13472-13483
101. Nakai J., Imagawa T., Hakamata Y., Shigekawa M., Takeshima H., and Numa S. Primary structure and functional expression from cDNA of the cardiac ryanodine receptor/calcium release channel. FEBS Lett. 271 (1990) 169-177
102. Vinet L., Rouet-Benzineb P., Marniquet X., Pellegrin N., Mangin L., Louedec L., et al. Chronic doxycycline exposure accelerates left ventricular hypertrophy and progression to heart failure in mice after thoracic aorta constriction. Am. J. Physiol. Heart Circ. Physiol. 295 (2008) H352-H360
103. Maillet M., Purcell N.H., Sargent M.A., York A.J., Bueno O.F., and Molkentin J.D. DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility. J. Biol. Chem. 283 (2008) 31246-31255
104. Kerkelä R., Kockeritz L., Macaulay K., Zhou J., Doble B.W., Beahm C., et al. Deletion of GSK-3$ in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J. Clin. Invest. 118 (2008) 3609-3618